Millennium Management’s Impact BioMedical IBO Stock Holding History

Millennium Management’s Portfolio IBO Stock Details IBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-137,823	Closed	-$69.6K	–	6524
2025 Q4	$69.6K	Buy	+137,823	New	+$72.9K	﹤0.01%	5689

Other funds holding IBO

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VGA

Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

MAC

Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Millennium Management's IBO Position: Q1 2026 in Review

Millennium Management sold out of Impact BioMedical (IBO) in Q1 2026, closing a stake of 137,823 shares — an estimated $69.6K sold.

Millennium Management first reported a position in IBO in Q4 2025 and held it in 1 quarter. The position peaked at $69.6K in Q4 2025. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

Millennium Management reported no remaining Impact BioMedical position as of Q1 2026 after selling out during the quarter.
Millennium Management sold 137,823 Impact BioMedical shares in Q1 2026, an estimated $69.6K.
Millennium Management first reported a position in Impact BioMedical in Q4 2025 and held it in 1 quarter.
Millennium Management's Impact BioMedical position peaked at $69.6K in Q4 2025.
20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.